Zurich Cantonal Bank’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,895
| Closed | -$203K | – | 2663 |
|
|
2020
Q3 | $203K | Hold |
5,895
| – | – | ﹤0.01% | 1576 |
|
|
2020
Q2 | $99K | Buy |
5,895
+3,286
| +126% | +$55.8K | ﹤0.01% | 1949 |
|
|
2020
Q1 | $38K | Hold |
2,609
| – | – | ﹤0.01% | 2074 |
|
|
2019
Q4 | $87K | Hold |
2,609
| – | – | ﹤0.01% | 1807 |
|
|
2019
Q3 | $55K | Hold |
2,609
| – | – | ﹤0.01% | 1978 |
|
|
2019
Q2 | $54K | Hold |
2,609
| – | – | ﹤0.01% | 2015 |
|
|
2019
Q1 | $58K | Hold |
2,609
| – | – | ﹤0.01% | 1911 |
|
|
2018
Q4 | $62K | Buy |
2,609
+708
| +37% | +$18.3K | ﹤0.01% | 1905 |
|
|
2018
Q3 | $52K | Hold |
1,901
| – | – | ﹤0.01% | 2140 |
|
|
2018
Q2 | $51K | Sell |
1,901
-589
| -24% | -$18K | ﹤0.01% | 2122 |
|
|
2018
Q1 | $79K | Buy |
2,490
+962
| +63% | +$33.9K | ﹤0.01% | 1750 |
|
|
2017
Q4 | $58K | Buy |
1,528
+449
| +42% | +$14.5K | ﹤0.01% | 1951 |
|
|
2017
Q3 | $27K | Hold |
1,079
| – | – | ﹤0.01% | 2150 |
|
|
2017
Q2 | $22K | Sell |
1,079
-4,900
| -82% | -$93.5K | ﹤0.01% | 2225 |
|
|
2017
Q1 | $130K | Buy |
5,979
+4,900
| +454% | +$101K | ﹤0.01% | 1187 |
|
|
2016
Q4 | $22K | Buy |
+1,079
| New | +$22.1K | ﹤0.01% | 2237 |
|
Zurich Cantonal Bank's AIMT Position: Q4 2020 in Review
Zurich Cantonal Bank sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 5,895 shares — an estimated $203K sold.
Zurich Cantonal Bank first reported a position in AIMT in Q4 2016 and held it in 16 quarters. The position peaked at $203K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Zurich Cantonal Bank reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Zurich Cantonal Bank sold 5,895 Aimmune Therapeutics shares in Q4 2020, an estimated $203K.
- Zurich Cantonal Bank first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 16 quarters.
- Zurich Cantonal Bank's Aimmune Therapeutics position peaked at $203K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Zurich Cantonal Bank's 13F filing for Q4 2020, filed 28 Jan 2021.